2965-22-2

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-FLUORO-5-NITROBENZOATE is used as a key intermediate for the synthesis of various pharmaceuticals, leveraging its strong functional groups and the presence of a fluorine atom to improve the properties and efficacy of the resulting drugs.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 2-FLUORO-5-NITROBENZOATE is utilized as a building block for the development of new agrochemicals, contributing to the creation of more effective and targeted pest control solutions.
Used in Fine Chemicals Industry:
METHYL 2-FLUORO-5-NITROBENZOATE is employed as an essential component in the production of fine chemicals, where its unique structural features and reactivity are harnessed to produce high-quality specialty chemicals for various applications.
Used in Medicinal Chemistry Research:
METHYL 2-FLUORO-5-NITROBENZOATE is used as a valuable tool in medicinal chemistry research for the design and development of new drugs, taking advantage of its fluorine-containing structure to explore novel therapeutic avenues and improve drug performance.

InChI:InChI=1/C8H6FNO4/c1-14-8(11)6-4-5(10(12)13)2-3-7(6)9/h2-4H,1H3

Upstream product

• 6307-82-0 2-chloro-5-nitro-benzoic acid methyl ester 
• 67-56-1 methanol 
• 445-29-4 o-fluoro-benzoic acid 
• 7304-32-7 2-fluoro-5-nitrobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 80-48-8 methyl p-toluene sulfonate 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 74-88-4 methyl iodide 
• 56741-33-4 5-amino-2-fluorobenzoic acid 

Downstream Products

• 87370-87-4 2,4,6-Tripyrrolidino-2'-(methoxycarbonyl)-4'-nitrobiphenyl 
• 56741-34-5 methyl 5-amino-2-fluorobenzoate 
• 476352-58-6 2-(3-cyano-phenoxy)-5-nitro-benzoic acid methyl ester 
• 660856-14-4 2-indazol-2-yl-5-nitro-benzoic acid methyl ester 
• 943513-57-3 2-[(2-methoxyethyl)methylamino]-5-nitrobenzoic acid methyl ester 
• 83909-55-1 methyl 2-(N-morpholino)-5-nitrobenzoate 
• 125568-75-4 methyl 3-azido-6-fluorobenzoate 
• 125568-81-2 methyl N-benzyl-3-amino-6-fluorobenzoate 
• 125568-87-8 3,3'-dicarbomethoxy-4,4'-difluoroazobenzene 
• 735213-47-5 methyl 2-(4-methyl-piperazin-1-yl)-5-nitro-benzoate 
• 1030187-45-1 methyl 2-[(4-hydroxycyclohexyl)amino]-5-nitrobenzoate 
• 280772-27-2 methyl 5-Nitro-2-[1-(pyridin-4-yl)piperidin-4-ylmethylamino]benzoate 
• 862125-43-7 methyl 5-nitro-2-(2',3',4',6'-tetra-O-acetyl-α-D-galactopyranosyloxy)benzoate 
• 313533-91-4 2-fluoro-4-methoxy-5-nitro-benzoic acid methyl ester 

Relevant academic research and scientific papers

Proximity effects in the palladium-catalyzed substitution of aryl fluorides

(Chemical Equation Presented) The aryl fluoride bond has long been considered inert toward Pd-catalyzed insertion reactions. This paper reports for the first time that aryl fluorides bearing an o-carboxylate group can undergo Pd-catalyzed couplings. On th

HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the programmed necrosis pathway.

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

The mitogen-activated protein kinase (MAP) kinase 4 (MKK4) was found to be a major regulator of liver regeneration and could be a valuable drug target addressing liver related diseases by restoring its intrinsic regenerative capacity. We report on the synthesis and optimization of novel MKK4 inhibitors following a target-hopping strategy from the FDA-approved BRAFV600E inhibitor PLX4032 (8). Applying an iterative multi-parameter optimization process we carved out essential structural features yielding in compounds with a low nanomolar affinity for MKK4 and excellent selectivity profiles against the main off-targets MKK7 and JNK1, which, upon relevant inhibition, would totally abrogate the pro-regenerative effect of MKK4 inhibition, as well as against the off-targets MAP4K5, ZAK and BRAF with selectivity factors ranging from 40 to 430 for our best-balanced compounds 70 and 73.

FUSED BICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE

Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1. Further provided are a pharmaceutical composition and a method of treating a disease regulated by ASK1 comprising administering the compounds or pharmaceutical composition thereof.

PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2 H,4 H)-diones as human immunodeficiency virus type 1 integrase inhibitors

We report herein further insight into the biological activities displayed by a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs). Substitution of the N-hydroxyimide two-metal binding pharmacophore at position 4 by carboxamido side chains was previously shown by us to be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitors in the low nanomolar range associated with low micromolar anti-HIV activities were obtained. We investigated the influence of substitution at position 7 on biological activity. Introduction of electron-withdrawing functional groups such as the nitro moiety at position 7 led to a noticeable improvement of antiviral activity, down to low nanomolar anti-HIV potencies, with advantageous therapeutic indexes going close to those of the clinically used raltegravir and retained potencies against a panel of IN mutants.

2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS

The present invention relates to compounds and compositions acting as inhibitors of HIV integrase. The compound of the invention is of Formula (I), or a tautomer (I') thereof, or a pharmaceutically acceptable salt, or solvate of said compound or tautomer

MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF

The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Synthesis and the crystal structure of (E)-2-(7-(3-(Thiophen-2-yl) acrylamido)-2,3-dihydro-5-oxobenzo[e][1,4]oxazepin-1(5H)-yl)ethyl acetate

Details of the synthesis and crystal structure determination of (E)-2-(7-(3-(thiophen-2-yl)acrylamido)-2,3-dihydro-5-oxobenzo[e][1,4] oxazepin-1(5H)-yl)ethyl acetate are presented. The compound crystallizes in the triclinic P-1 space group (a = 8.3377(17)